

## **ALZHEIMER'S THERAPY INFUSION ORDERS**

**P:** 877.365.5566 | **F:** 855.889.2946

PATIENT	INFORMATION:	Fax completed form, insur	ance information,	and clinical documentation to 855.889.2946	
Patient Name:			_ DOB:	Phone:	
		✓ □ Continuing Therapy	Next Treatn	nent Date:	
	INFORMATION				
Diagnosis:	Alzheimer's Disease with Early Onset (ICD-10 code: G30.0)				
☐ Alzheimer's Disease with Late Onset (ICD-10 code: G30.1)					
	☐ Other Alzheimer's Disease (ICD-10 code: G30.8)				
	☐ Alzheimer's Disease, unspecified (ICD-10 code: G30.9)				
	☐ Mild cognitive impairment, so stated (ICD-10 code: G31.84) -AND-				
☐ Encounter for clinical registry program (ICD-10 code: Z00.6), <b>Medicare require</b>					
Patient Wei	ight: <b>kg</b> (re	quired) Allergies:			
THERAPY	ORDER				
-	☐ 10mg/kg IV eve	•			
(lecanemab)	☐ 10mg/kg IV eve	ry 4 weeks (after 18 mont	hs of treatment	, patient can transition to q 4 weeks*)	
• MRI	s should be performe	to every 4 weeks <u>after</u> ed at baseline & prior to ot performed at indica	the 5 <sup>th</sup> , 7 <sup>th</sup> , a	remain on every 2 weeks and 14 <sup>th</sup> infusion	
(donanemab)  • MRI:	th  Maintenance: 14 s should be performe	ereafter 400mg IV every 4 wee ed at baseline & prior to ot performed at indica	ks o the 2 <sup>nd</sup> , 3 <sup>rd</sup> , 4	nen 1400mg IV every 4 weeks 4 <sup>th</sup> , and 7 <sup>th</sup> infusion	
Refill for:	] 6 months ☐ 1 yea	r 🗌 Other:			
Additional	orders:				
				ncy:	
		☐ Paragon ☐ Referrin			
	R INFORMATION				
agent in dealing wit	h medical and prescription insurance of	companies, and to select the preferred site	of care for the patient.	our prior authorization and specialty pharmacy designated	
Provider Na	me:	Signature: _		Date: Contact Person:	
□ Opt out o	of Paragon selecting site	e rax e of care (if checked, plea	se list site of c	care):	
	ED LOCATION				
City:	Stat	re:	View	our locations here:	
		PARAGONHEAI THCAE	E COM		

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





## COMPREHENSIVE SUPPORT FOR ALZHEIMER'S THERAPY

A Carelon Company

PATIENT INFORMATION:					
Patient Name: DOB:					
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL					
<ul> <li>☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)</li> <li>☐ Include patient demographic information and insurance information</li> <li>☐ Include patient's medication list</li> <li>☐ Supporting clinical notes (H&amp;P) to support primary diagnosis</li> <li>☐ Other medical necessity:</li> </ul>					
REQUIRED					
☐ Patient enrolled in the CMS National Patient Registry (Medicare & Medicare Advantage required)					
Issue number: Date of registry enrollment:					
☐ Provide copy of CMS national patient registry confirmation					
https://qualitynet.cms.gov/alzheimers-ced-registry/submission					
☐ Confirmed presence of amyloid pathology					
Attach results: Amyloid PET scan $\overline{OR}$ +CSF (cerebrospinal fluid)					
☐ MRI of the brain (within 1 year) - attach results					
☐ Cognitive assessment scores (list all available, attach results):					
☐ MMSE: Score Date of assessment					
☐ MoCA: Score Date of assessment					
☐ CDR: Score Memory box: Score Date of assessment					
☐ Other: Score Date of assessment					
☐ Functional assessment score: (attach results)					
Assessment Name:   FAQ FAST Other: Assessment date:					
☐ Include labs and/or test results for the following:					
☐ Genotype testing for ApoE4					
- OR -					
ApoE4 genetic testing has NOT been completed. Provider has counselled the patient on how testing for ApoE4 status informs the risk of developing ARIA and the patient has shared decision-making to initiate Legembi					
$\square$ Does the patient have objective impairment in episodic memory as evidenced by a					
memory test (i.e., Free and Cued, Wechsler, etc.)? (BCBS required) ☐ Yes ☐ No					
☐ Is the patient on therapeutic anticoagulation/antiplatelet therapy? ☐ Yes ☐ No					
If yes, please note therapy and dose:					

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance